Clearfield, Inc. — Financial Data
Annual figures from SEC EDGAR XBRL filings (10-K)
These figures are extracted directly from XBRL-tagged financial statements that Clearfield, Inc. filed with the SEC as part of its annual 10-K reports. XBRL (eXtensible Business Reporting Language) is a structured data format the SEC requires for machine-readable financial disclosures. Values shown are as reported — negative figures indicate a loss and are shown in red.
Revenue
Total revenue from all business activities — the top line of the income statement. Represents all money earned before any expenses are deducted.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2019 | Sep 30, 2019 | $85.03M | Nov 15, 2019 |
| FY2019 | Sep 30, 2018 | $77.65M | Nov 15, 2019 |
| FY2019 | Sep 30, 2017 | $73.95M | Nov 15, 2019 |
| FY2018 | Sep 30, 2016 | $75.29M | Nov 14, 2018 |
| FY2014 | Sep 30, 2014 | $58.05M | Nov 26, 2014 |
| FY2014 | Sep 30, 2013 | $53.35M | Nov 26, 2014 |
| FY2014 | Sep 30, 2012 | $37.47M | Nov 26, 2014 |
| FY2012 | Sep 30, 2011 | $35.19M | Dec 4, 2012 |
| FY2011 | Sep 30, 2010 | $24.37M | Nov 30, 2011 |
Revenue
Revenue recognized from contracts with customers under ASC 606, excluding taxes collected on behalf of government authorities. This is the primary revenue concept for many companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $150.13M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $125.57M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $34.23M | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | $225.72M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $85.94M | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | $270.88M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $140.76M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $93.08M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $85.03M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $77.65M | Nov 15, 2019 |
Revenue (Net Sales)
Net sales revenue — gross revenue less returns, allowances, and discounts. Used by many manufacturers and retailers as the primary top-line figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2017 | Sep 30, 2017 | $73.95M | Nov 15, 2017 |
| FY2017 | Sep 30, 2016 | $75.29M | Nov 15, 2017 |
| FY2017 | Sep 30, 2015 | $60.32M | Nov 15, 2017 |
| FY2016 | Sep 30, 2014 | $58.05M | Nov 22, 2016 |
| FY2015 | Sep 30, 2013 | $53.35M | Nov 25, 2015 |
Gross Profit
Revenue minus the cost of goods sold (COGS). Gross profit shows how much revenue remains to cover operating expenses, R&D, and administrative costs before calculating operating income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $50.54M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $25.85M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $4.70M | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | $79.86M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $30.65M | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | $112.95M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $61.18M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $37.92M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $32.69M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $31.00M | Nov 15, 2019 |
Net Income
The bottom-line profit — what remains after all operating expenses, interest, taxes, and other costs are deducted. A negative value means the company reported a net loss for the year.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | ($8.05M) | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($12.45M) | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | ($5.27M) | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | $32.53M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $14.26M | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | $49.36M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $20.33M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $7.29M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $4.57M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $4.27M | Nov 15, 2019 |
Operating Income
Profit from core business operations before interest expense and income taxes (also known as EBIT). Excludes non-operating items, making it a cleaner measure of operational efficiency than net income.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.12M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | ($19.23M) | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | ($8.16M) | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | $37.58M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $17.89M | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | $63.82M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $25.23M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $8.38M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $5.19M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $5.07M | Nov 15, 2019 |
R&D Expense
Spending on research and development activities — developing new products, improving existing ones, or conducting basic research. High R&D relative to revenue is common in technology and pharmaceutical companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $2.42M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $3.00M | Nov 25, 2025 |
| FY2025 | Sep 30, 2023 | $3.12M | Nov 25, 2025 |
| FY2024 | Sep 30, 2022 | $895.0K | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $243.0K | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $1.27M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $1.09M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $787.4K | Nov 15, 2019 |
| FY2019 | Sep 30, 2017 | $865.6K | Nov 15, 2019 |
| FY2018 | Sep 30, 2016 | $838.1K | Nov 14, 2018 |
SG&A Expense
Selling, general, and administrative expenses — the overhead costs of running the business, including salaries, marketing, legal fees, and corporate office costs. Excludes COGS and R&D.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $48.42M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $45.08M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $12.86M | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | $42.28M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $12.76M | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | $49.13M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $35.94M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $29.53M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $27.50M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $25.93M | Nov 15, 2019 |
Operating Cash Flow
Cash generated from core business operations — a more reliable measure of financial health than net income because it strips out non-cash items like depreciation and one-time charges.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $22.22M | Nov 15, 2024 |
| FY2024 | Dec 31, 2023 | $7.83M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | $18.42M | Nov 15, 2024 |
| FY2024 | Dec 31, 2022 | $1.10M | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | $2.26M | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | $10.90M | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | $6.66M | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | $14.73M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $4.55M | Nov 15, 2019 |
| FY2019 | Sep 30, 2017 | $6.30M | Nov 15, 2019 |
Capital Expenditures (Capex)
Cash spent on acquiring or upgrading physical assets — property, equipment, and infrastructure. High capex businesses include manufacturing, telecom, and energy companies.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2024 | Sep 30, 2024 | $9.57M | Nov 15, 2024 |
| FY2024 | Dec 31, 2023 | $2.35M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | $7.68M | Nov 15, 2024 |
| FY2024 | Dec 31, 2022 | $1.98M | Feb 5, 2024 |
| FY2023 | Sep 30, 2022 | $8.50M | Nov 29, 2023 |
| FY2020 | Sep 30, 2020 | $1.81M | Nov 12, 2020 |
| FY2020 | Sep 30, 2019 | $2.51M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $1.19M | Nov 15, 2019 |
| FY2019 | Sep 30, 2017 | $2.02M | Nov 15, 2019 |
| FY2018 | Sep 30, 2016 | $1.55M | Nov 14, 2018 |
Total Assets
The total value of everything the company owns or controls — cash, investments, receivables, property, equipment, and intangibles. Reported as of fiscal year end.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $306.17M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $315.28M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $335.63M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | $355.52M | Nov 15, 2024 |
| FY2024 | Dec 31, 2022 | $351.80M | Feb 5, 2024 |
| FY2023 | Sep 30, 2022 | $229.13M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $125.91M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $95.30M | Nov 10, 2021 |
| FY2020 | Sep 30, 2019 | $81.89M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $74.23M | Nov 15, 2019 |
Total Liabilities
All financial obligations owed to outside parties — including debt, accounts payable, accrued expenses, and deferred revenue. Subtracting liabilities from total assets gives stockholders' equity.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $50.01M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $39.51M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $35.53M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | $40.35M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $81.55M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $22.09M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $12.54M | Nov 10, 2021 |
| FY2020 | Sep 30, 2019 | $6.96M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $5.35M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $4.97M | Nov 14, 2018 |
Stockholders Equity
The net worth attributable to shareholders: total assets minus total liabilities. Also called book value. Can be negative if liabilities exceed assets, which is common in capital-intensive industries.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $256.16M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $275.76M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $300.10M | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | $315.16M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $293.88M | Feb 5, 2024 |
| FY2025 | Sep 30, 2022 | $147.58M | Nov 25, 2025 |
| FY2024 | Sep 30, 2021 | $103.82M | Nov 15, 2024 |
| FY2023 | Sep 30, 2020 | $82.75M | Nov 29, 2023 |
| FY2022 | Sep 30, 2019 | $74.93M | Nov 23, 2022 |
| FY2020 | Sep 30, 2018 | $68.87M | Nov 12, 2020 |
Goodwill
An intangible asset representing the premium paid above fair value when acquiring another company. A large goodwill balance signals a history of acquisitions at premium prices.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $4.71M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $6.63M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $6.53M | Nov 15, 2024 |
| FY2025 | Sep 30, 2023 | $6.53M | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | $6.40M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $6.40M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $4.71M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $4.71M | Nov 10, 2021 |
| FY2020 | Sep 30, 2019 | $4.71M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $4.71M | Nov 15, 2019 |
Retained Earnings
Cumulative net income kept by the company rather than distributed as dividends. A growing retained earnings balance indicates consistent profitability; a deficit indicates cumulative losses.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $106.91M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $114.96M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $122.15M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | $127.34M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $94.80M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $45.44M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $25.11M | Nov 10, 2021 |
| FY2020 | Sep 30, 2019 | $17.82M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $13.25M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | $8.98M | Nov 14, 2018 |
Cash & Equivalents
Highly liquid assets the company holds — cash on hand, bank balances, and short-term investments with maturities of three months or less. A key indicator of short-term financial health.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | $21.49M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | $14.15M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | $34.48M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | $37.83M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | $16.65M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | $13.22M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | $16.45M | Nov 10, 2021 |
| FY2020 | Sep 30, 2019 | $10.08M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | $8.55M | Nov 15, 2019 |
| FY2019 | Sep 30, 2017 | $18.54M | Nov 15, 2019 |
Long-Term Debt
Debt obligations due more than one year from the balance sheet date — bonds, term loans, and notes payable. High long-term debt relative to equity can signal elevated financial leverage.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2022 | Sep 30, 2021 | $0 | Nov 23, 2022 |
EPS (Basic)
Net income divided by the weighted average shares outstanding. Basic EPS does not account for dilutive securities like options or convertible bonds — use diluted EPS for a more conservative view.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | 2 | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | 1 | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | 3 | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | 1 | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | 0 | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | 0 | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Nov 15, 2019 |
EPS (Diluted)
Net income divided by the fully diluted share count — including all potential shares from options, warrants, and convertible instruments. The more conservative and widely cited EPS figure.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 0 | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 0 | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | 0 | Feb 5, 2024 |
| FY2025 | Sep 30, 2023 | 2 | Nov 25, 2025 |
| FY2024 | Dec 31, 2022 | 1 | Feb 5, 2024 |
| FY2024 | Sep 30, 2022 | 3 | Nov 15, 2024 |
| FY2023 | Sep 30, 2021 | 1 | Nov 29, 2023 |
| FY2022 | Sep 30, 2020 | 0 | Nov 23, 2022 |
| FY2020 | Sep 30, 2019 | 0 | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | 0 | Nov 15, 2019 |
Shares Outstanding
Total common shares issued and held by all shareholders, excluding treasury shares. Combined with market price gives market capitalization.
| Fiscal Year | Period End | Value | Filed |
|---|---|---|---|
| FY2025 | Sep 30, 2025 | 13.84M | Nov 25, 2025 |
| FY2025 | Sep 30, 2024 | 14.23M | Nov 25, 2025 |
| FY2024 | Dec 31, 2023 | 14.94M | Feb 5, 2024 |
| FY2024 | Sep 30, 2023 | 15.25M | Nov 15, 2024 |
| FY2023 | Sep 30, 2022 | 13.82M | Nov 29, 2023 |
| FY2022 | Sep 30, 2021 | 13.73M | Nov 23, 2022 |
| FY2021 | Sep 30, 2020 | 13.65M | Nov 10, 2021 |
| FY2020 | Sep 30, 2019 | 13.64M | Nov 12, 2020 |
| FY2019 | Sep 30, 2018 | 13.65M | Nov 15, 2019 |
| FY2018 | Sep 30, 2017 | 13.81M | Nov 14, 2018 |